Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Obeticholic acid (OCA), also known as 6-ethylchenodeoxycholic acid, is a second-generation bile acid derivative primarily utilized in the management of chronic liver diseases. Its molecular formula is C24H38O4, and it carries the unique CAS registry number 125901-27-9. Structurally, OCA serves as an agonist for the farnesoid X receptor (FXR), a nuclear receptor that plays a pivotal role in regulating bile acid homeostasis, glucose metabolism, and lipid synthesis. By activating FXR, Obeticholic acid exerts potent anti-fibrotic, anti-inflammatory, and choleretic effects within the hepatic system.
The primary clinical indication for this pharmaceutical agent is the treatment of adults with primary biliary cholangitis (PBC). It is specifically approved for patients who have had an inadequate response to ursodeoxycholic acid or those who cannot tolerate this first-line therapy. In PBC, OCA helps reduce serum alkaline phosphatase levels and improves histological features of liver fibrosis. Beyond its established use in PBC, ongoing research is exploring its potential efficacy in other metabolic liver conditions, including non-alcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatotic liver disease (MASLD), although regulatory approvals for these indications vary by region and are subject to further clinical validation.
Pharmacologically, Obeticholic acid is available in oral tablet form, typically dosed once daily. Due to its mechanism of action, common adverse events may include pruritus, fatigue, and abdominal pain. Clinicians must monitor patients closely for signs of hepatic decompensation, particularly in those with advanced cirrhosis, as the drug can exacerbate portal hypertension in specific populations. Despite these risks, OCA represents a significant therapeutic advancement, offering a targeted approach to slowing disease progression in chronic cholestatic disorders where previous options were limited. As global research continues into liver pathophysiology, Obeticholic acid remains a cornerstone in the evolving landscape of hepatology, providing hope for improved long-term outcomes for millions of patients worldwide suffering from progressive liver damage.